Clinical-grade iPSC-derived chondrogenic micropellets for treating advanced cartilage defects

Area of Science:

• Regenerative Medicine
• Orthopedics
• Stem Cell Biology

Background:

• Cartilage defects in osteoarthritis (OA) have limited self-repair capacity.
• Current treatments for OA often involve invasive procedures or have limited efficacy.
• Allogeneic transplantation is a potential therapy, but less invasive delivery methods are needed.

Purpose of the Study:

• To develop iPSC-derived "minimal injectable unit" chondrogenic micropellets (MIUChons) for intra-articular injection in OA therapy.
• To optimize clinical-grade production of iPSC-derived injectable chondrogenic spheroids.
• To evaluate the efficacy of MIUChons in preclinical OA models.

Main Methods:

• Optimization of good manufacturing practice (GMP) or clinical-grade production of iPSC-derived chondrogenic spheroids.
• Development of "minimal injectable unit" chondrogenic micropellets (MIUChons).
• Intra-articular injection of MIUChons into OA animal models, followed by in vivo and in vitro analyses.

Main Results:

• MIUChon treatment effectively reduced cartilage degeneration and deterioration in OA models.
• Intra-articular injection of MIUChons improved arthritis symptoms.
• In vitro and in vivo analyses confirmed the therapeutic potential of MIUChons.

Conclusions:

• iPSC-derived MIUChons represent a promising, minimally invasive strategy for treating cartilage deterioration in OA.
• Intra-articular injection of MIUChons offers a novel cell-based therapeutic approach for OA.
• This study demonstrates the feasibility of using engineered iPSC-derived tissues for cartilage repair.